LB Pharmaceuticals
LBRX
77 hedge funds and large institutions have $692M invested in LB Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 10 closing their positions.
388% more capital inflows, than outflows
Capital inflows: $132M | Capital outflows: $27M
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
13% more funds holding
Funds holding: 68 → 77 (+9)
0.39% more ownership
Funds ownership: 97.99% → 98.38% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caligan Partners
New York
|
+$33.2M |
| 2 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.72M |
| 3 |
Spruce Street Capital
New York
|
+$8.55M |
| 4 |
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$7.63M |
| 5 |
Great Point Partners
Greenwich,
Connecticut
|
+$6.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
-$6.57M |
| 2 |
Jennison Associates
New York
|
-$6.54M |
| 3 |
JP Morgan Chase
New York
|
-$4.24M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.97M |
| 5 |
Longbow Finance
Lutry,
Switzerland
|
-$1.83M |
LBRX Hedge Fund Activity: Q1 2026 in Review
77 of the 8,217 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q1 2026, worth a combined $692M — up 25% from $552M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LBRX positions and 10 closed out — a net gain of 10 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was Caligan Partners, opening a new position worth an estimated $33.2M. The largest seller was Logos Global Management, cutting an estimated $6.57M.
- 77 institutional investors held LB Pharmaceuticals (LBRX) as of Q1 2026, up from 68 in Q4 2025.
- Funds reported $692M of LB Pharmaceuticals stock for Q1 2026, up 25% quarter-over-quarter.
- 20 funds opened new LB Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +10 holders.
- The largest LB Pharmaceuticals buyer in Q1 2026 was Caligan Partners, an estimated $33.2M added.
- The largest LB Pharmaceuticals seller in Q1 2026 was Logos Global Management, an estimated $6.57M sold.
Based on aggregated 13F filings for Q1 2026.